

**Product Name** : Tanzisertib

**Synonyms** : CC-930


**Cat No.** : M22926

**CAS Number** : 899805-25-5

**Molecular Formula** : C<sub>21</sub>H<sub>23</sub>F<sub>3</sub>N<sub>6</sub>O<sub>2</sub>

**Formula Weight** : 448.44

**Chemical Name** : —



**Description** : Tanzisertib (CC-930) is a potent inhibitor of JNK1/2/3 with IC<sub>50</sub>s of 61/7/6 nM, respectively, with potential antifibrotic activity. Tanzisertib (CC-930) inhibits the formation of phospho-cJun in human PBMC stimulated by phorbol-12-myristate-13-acetate and phytohemagglutinin (IC<sub>50</sub>=1 μM) and it blocks the JNK pathway that is activated by pro-fibrotic cytokines in systemic sclerosis. Tanzisertib (CC-930) (1-2 μM) substantially reduces hepatocyte apoptosis and necrosis, abrogates apoptosis and necrosis in FC-loaded WT hepatocytes. Tanzisertib (CC-930) (10 and 30 mg/kg, p.o.) inhibits the production of TNFα by 23% and 77% in the acute rat LPS-induced TNFα production PK-PD model. Tanzisertib (CC-930) (150 mg/kg) prevents the development of fibrosis in different models. However, it can also induce the regression of pre-existing fibrosis.

**Pathway** : MAPK/ERK Signaling

**Target** : JNK

**Receptor** : JNK3;JNK2;JNK1

**Solubility** : DMSO:33 mg/mL (73.59 mM)

**SMILES** : O[C@H]1CC[C@@H](CC1)NC2=NC=C3N=C(N(C3=N2)[C@@H]4COCC4)NC5=C(C=C(C=C5F)F)F

**Storage** : (-20°C)

**Stability** : ≥ 2 years

**Reference** :

1. Plantevin Krenitsky V, et al. Discovery of CC-930, an orally active anti-fibrotic JNK inhibitor. Bioorg Med Chem Lett. 2012 Feb 1;22(3):1433-8.